MedPath

A multicentre, double blind, placebo controlled, randomised trial to evaluate the effectiveness of a one-day versus seven-day regimen of nitrofurantoin for the treatment of asymptomatic bacteriuria in pregnancy

Not Applicable
Completed
Conditions
Asymptomatic Bacteriuria (ASB)
Infections and Infestations
Bacteriuria
Registration Number
ISRCTN11966080
Lead Sponsor
World Health Organization (WHO) (Switzerland)
Brief Summary

2009 results in https://pubmed.ncbi.nlm.nih.gov/19155904/ (added 30/12/2020)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
778
Inclusion Criteria

1. Pregnant women with gestational age 12 - 32 weeks
2. Willing and able to give consent

Exclusion Criteria

1. Have any underlying disease, which require continuous steroid and/or antibiotic treatment, e.g. systemic lupus erythematosus, valvular heart disease, etc.
2. Use of any antibiotics during the past one-week
3. Received any treatment for urinary tract infection at any time during the current pregnancy
4. History of nitrofurantoin hypersensitivity
5. Plan not to deliver at the study hospital
6. Any symptoms such as flank pain, dysuria that suggests symptomatic Urinary Tract Infections (UTI)
7. Have any haematological disease including Glucose-6-Phosphate Dehydrogenase deficiency (G6PD)
8. Negative urine dipslide
9. Negative urine culture
10. Positive urine culture but the organism is resistant to Nitrofurantoin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Bacteriological cure after the antibiotic treatment based on the result of midstream urine culture 14 days after the initiation of the treatment.
Secondary Outcome Measures
NameTimeMethod
<br> Incidences of:<br> 1. Pyelonephritis<br> 2. Preterm delivery<br> 3. Low birth weight<br> 4. Side effects<br>
© Copyright 2025. All Rights Reserved by MedPath